The long-awaited study, which was commissioned by the FDA in hopes of reducing racial bias, found results that contradict past research findings, leaving clinicians confused. Also: FDA Commissioner ...

LSD is a drug often associated with the counter-culture of the 1960s. But it is being studied as a promising therapy for ...

Definium’s late-stage pipeline includes four Phase 3 trials—two each for GAD and MDD—anchored by its lead candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD.

San Francisco’s UCSF is stepping into the national spotlight as one of several university medical centers testing whether a ...

UCSF is seeking volunteers for a trial using LSD to treat generalized anxiety disorder - a poorly understood and potentially ...

The results from drugmaker Mindmed tested several doses of LSD in patients with moderate-to-severe generalized anxiety ...

Detailed price information for Betterlife Pharma Inc (BETRF) from The Globe and Mail including charting and trades.

Two later-stage trials investigating LSD for treating anxiety are due to conclude in 2026, which could lead to the drug being approved for the common mental health condition ...

A mid-stage study of a pharmaceutical version of the psychedelic LSD reported the drug might help alleviate anxiety symptoms for up to three months, advancing a potential treatment for the most common ...

WASHINGTON (AP) — LSD reduced symptoms of anxiety in a midstage study published Thursday, paving the way for additional testing and possible medical approval of a psychedelic drug that has been banned ...

A rigorous new study finds that a single dose of LSD can ease anxiety and depression for months. The study involved 198 adults with generalized anxiety disorder, or GAD, a disabling form of anxiety ...